
USPH Stock Forecast & Price Target
USPH Analyst Ratings
Bulls say
US Physical Therapy has demonstrated a solid financial performance, with commercial pricing increasing sequentially by 2.2%, suggesting effective pricing strategies that enhance revenue potential. Additionally, the company's Industrial Injury Prevention (IIP) revenue has seen impressive growth of 22.2% overall and 18.4% when excluding the impact of mergers and acquisitions, indicating strong core business performance. Furthermore, the recent increase in the net rate for the newly acquired Metro business, from $101 to $107.50, underscores the successful integration and value enhancement of its acquisitions.
Bears say
US Physical Therapy Inc has experienced a 0.6% decline in a key financial metric, decreasing from $84.46 to $83.95 compared to the same period last year. The company has faced ongoing reimbursement cuts over the past five years, cumulatively resulting in a $20 million reduction in profitability, which poses a significant risk to its financial stability. Additionally, operating expenses, including rent and clinic-related costs, rose to 20.2% of revenue, slightly above the projected 20.1%, indicating potential challenges in managing costs amidst fluctuating revenues.
This aggregate rating is based on analysts' research of U.S. Physical Therapy and is not a guaranteed prediction by Public.com or investment advice.
USPH Analyst Forecast & Price Prediction
Start investing in USPH
Order type
Buy in
Order amount
Est. shares
0 shares